Cargando…
Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen
INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is rapidly spreading all over the world. A new quantifying reagent for detecting SARS-CoV-2 antigen was developed for early and accurate detection. We evaluated the novel quantitative reagent for detecting SARS-CoV-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836628/ https://www.ncbi.nlm.nih.gov/pubmed/33546959 http://dx.doi.org/10.1016/j.jiac.2021.01.007 |
_version_ | 1783642790577569792 |
---|---|
author | Kobayashi, Ryo Murai, Ryosei Asanuma, Koichi Fujiya, Yoshihiro Takahashi, Satoshi |
author_facet | Kobayashi, Ryo Murai, Ryosei Asanuma, Koichi Fujiya, Yoshihiro Takahashi, Satoshi |
author_sort | Kobayashi, Ryo |
collection | PubMed |
description | INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is rapidly spreading all over the world. A new quantifying reagent for detecting SARS-CoV-2 antigen was developed for early and accurate detection. We evaluated the novel quantitative reagent for detecting SARS-CoV-2 antigen using an automated laboratory device. METHODS: One-hundred nasopharyngeal samples were collected from 47 SARS-CoV-2-infected patients, and 200 samples were collected from healthy donners. We measured the SARS-CoV-2 antigen and nucleic acid using Lumipulse Presto SARS-CoV-2 Ag and the 2019 Novel Coronavirus Detection Kit, respectively. RESULTS: The sensitivity and specificity of the SARS-CoV-2 antigen test were 75.7% (56/74) and 96.0% (192/200), respectively. The concordance rate in the positive group between the antigen and nucleic acid tests was 66% (66/100). In addition, the correlation coefficient between the concentration of SARS-CoV-2 antigen and the level of SARS-CoV-2 RNA was 0.74. There were 19 discrepant samples in which SARS-CoV-2 RNA was detected without SARS-CoV-2 antigen. There was significant difference between the discrepant and matched samples in terms of the time since symptom onset: the 19 discrepant samples were collected a median of 33 days after onset, while the 55 matched samples were collected a median of 19 days after onset. In addition, the 19 discrepant samples were collected from patients who were immune against SARS-CoV-2. CONCLUSIONS: This novel SARS-CoV-2 antigen detection assay is highly sensitive, rapid, accurate, easily diagnostic. It may be useful in both clinical diagnosis and in screening because it does not require special methods such as PCR. |
format | Online Article Text |
id | pubmed-7836628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78366282021-01-26 Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen Kobayashi, Ryo Murai, Ryosei Asanuma, Koichi Fujiya, Yoshihiro Takahashi, Satoshi J Infect Chemother Original Article INTRODUCTION: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is rapidly spreading all over the world. A new quantifying reagent for detecting SARS-CoV-2 antigen was developed for early and accurate detection. We evaluated the novel quantitative reagent for detecting SARS-CoV-2 antigen using an automated laboratory device. METHODS: One-hundred nasopharyngeal samples were collected from 47 SARS-CoV-2-infected patients, and 200 samples were collected from healthy donners. We measured the SARS-CoV-2 antigen and nucleic acid using Lumipulse Presto SARS-CoV-2 Ag and the 2019 Novel Coronavirus Detection Kit, respectively. RESULTS: The sensitivity and specificity of the SARS-CoV-2 antigen test were 75.7% (56/74) and 96.0% (192/200), respectively. The concordance rate in the positive group between the antigen and nucleic acid tests was 66% (66/100). In addition, the correlation coefficient between the concentration of SARS-CoV-2 antigen and the level of SARS-CoV-2 RNA was 0.74. There were 19 discrepant samples in which SARS-CoV-2 RNA was detected without SARS-CoV-2 antigen. There was significant difference between the discrepant and matched samples in terms of the time since symptom onset: the 19 discrepant samples were collected a median of 33 days after onset, while the 55 matched samples were collected a median of 19 days after onset. In addition, the 19 discrepant samples were collected from patients who were immune against SARS-CoV-2. CONCLUSIONS: This novel SARS-CoV-2 antigen detection assay is highly sensitive, rapid, accurate, easily diagnostic. It may be useful in both clinical diagnosis and in screening because it does not require special methods such as PCR. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021-06 2021-01-16 /pmc/articles/PMC7836628/ /pubmed/33546959 http://dx.doi.org/10.1016/j.jiac.2021.01.007 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Kobayashi, Ryo Murai, Ryosei Asanuma, Koichi Fujiya, Yoshihiro Takahashi, Satoshi Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen |
title | Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen |
title_full | Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen |
title_fullStr | Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen |
title_full_unstemmed | Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen |
title_short | Evaluating a novel, highly sensitive, and quantitative reagent for detecting SARS-CoV-2 antigen |
title_sort | evaluating a novel, highly sensitive, and quantitative reagent for detecting sars-cov-2 antigen |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836628/ https://www.ncbi.nlm.nih.gov/pubmed/33546959 http://dx.doi.org/10.1016/j.jiac.2021.01.007 |
work_keys_str_mv | AT kobayashiryo evaluatinganovelhighlysensitiveandquantitativereagentfordetectingsarscov2antigen AT murairyosei evaluatinganovelhighlysensitiveandquantitativereagentfordetectingsarscov2antigen AT asanumakoichi evaluatinganovelhighlysensitiveandquantitativereagentfordetectingsarscov2antigen AT fujiyayoshihiro evaluatinganovelhighlysensitiveandquantitativereagentfordetectingsarscov2antigen AT takahashisatoshi evaluatinganovelhighlysensitiveandquantitativereagentfordetectingsarscov2antigen |